Icecure Medical Ltd. (ICCM) has released an update.
IceCure Medical Ltd., known for its innovative cryoablation treatments, has filed for FDA clearance of its XSense™ System, which seeks to expand on the capabilities of its ProSense® System for minimally invasive tumor destruction. The XSense™ is designed to be a next-generation device, offering a single-probe cryoablation solution for various medical conditions, and represents IceCure’s commitment to advancing its market-leading cryoablation technology portfolio.
For further insights into ICCM stock, check out TipRanks’ Stock Analysis page.
